RADDIAL (Rare Disease Diagnosis Alliance) is an initiative of Sanofi, Takeda, Johnson & Johnson Innovative Medicine, Alnylam Pharmaceuticals and Chiesi. The aim of the alliance is to initiative a broad stakeholder dialogue aimed at optimising and shortening the diagnosis pathway for rare disease patients. The initiative is undertaken in close cooperation with patient association RaDiOrg which, as an independent partner, will ensure that the patient perspective remains central to the dialogue.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Brussels, Be
- Industry
- Hospitals And Health Care
- NAICS
-
Health Care and Social AssistanceSocial Assistance
- Website
- http://raddial.be
- HQ
- Brussels
- Competitors
- UCB Rare Disease Connect in Neurology, Sanofi Belgium, UZ Antwerpen, Rare Disease Clinical Trial Network, rAIre: Rare Disease Insights, Festival Imagésanté, Takeda in Belgium, IFB, Instituut Farmaceutische Bedrijfskunde, Rare Disease Research Network (RDRN), Rarely Considered: ideas for rare disease policy.
Raddial (Rare Disease Diagnosis Alliance) Questions
Raddial (Rare Disease Diagnosis Alliance)'s website is http://raddial.be
Raddial (Rare Disease Diagnosis Alliance)'s LinkedIn profile is https://be.linkedin.com/company/raddial
Raddial (Rare Disease Diagnosis Alliance) has
2 employees.
View email and phone details for 2
employees at Raddial (Rare Disease Diagnosis Alliance).
Raddial (Rare Disease Diagnosis Alliance)'s industry is
Hospitals and Health Care
Raddial (Rare Disease Diagnosis Alliance)'s top competitors are
Ucb Rare Disease Connect In Neurology,
Sanofi Belgium,
Uz Antwerpen,
Rare Disease Clinical Trial Network,
Raire: Rare Disease Insights,
Festival Imagésanté,
Takeda In Belgium,
Ifb, Instituut Farmaceutische Bedrijfskunde,
Rare Disease Research Network (Rdrn),
Rarely Considered: Ideas For Rare Disease Policy.
Raddial (Rare Disease Diagnosis Alliance)'s categories are Hospitals and Health Care
Raddial (Rare Disease Diagnosis Alliance)'s founding year is 2022
